Isu Abxis Co Ltd
KOSDAQ:086890
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4 980
7 900
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Isu Abxis Co Ltd
Accounts Receivables
Isu Abxis Co Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Isu Abxis Co Ltd
KOSDAQ:086890
|
Accounts Receivables
₩26.3B
|
CAGR 3-Years
55%
|
CAGR 5-Years
41%
|
CAGR 10-Years
28%
|
|
|
Celltrion Inc
KRX:068270
|
Accounts Receivables
₩963.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
3%
|
CAGR 10-Years
8%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Accounts Receivables
₩18.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Accounts Receivables
₩45.8B
|
CAGR 3-Years
18%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Accounts Receivables
₩32.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Accounts Receivables
₩10B
|
CAGR 3-Years
48%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
Isu Abxis Co Ltd
Glance View
ISU Abxis Co., Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Seongnam, Gyeonggi-Do and currently employs 143 full-time employees. The company went IPO on 2009-02-03. The firm operates its business under two divisions: antibody therapeutics business division and diagnostic business division. Its antibody therapeutics business division engages in the development of Cloticab, which is a monoclonal therapeutic antibody for thrombus. Its diagnostic business division engages in the provision of genetic testing services and chemotherapy response assay services for cancer examination.
See Also
What is Isu Abxis Co Ltd's Accounts Receivables?
Accounts Receivables
26.3B
KRW
Based on the financial report for Jun 30, 2024, Isu Abxis Co Ltd's Accounts Receivables amounts to 26.3B KRW.
What is Isu Abxis Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
28%
Over the last year, the Accounts Receivables growth was 40%. The average annual Accounts Receivables growth rates for Isu Abxis Co Ltd have been 55% over the past three years , 41% over the past five years , and 28% over the past ten years .
You don't have any saved screeners yet
